Company news

Genexine, Inc. news in 2026

Genexine, Inc.'s news releases, calls and decks from 2026, newest first.

View company

Genexine’s GX-BP1 (SOX2 bioPROTAC) Suppresses Tumor Regrowth despite Osimertinib and Dato-DXd Combination and Achieves 6/6 Complete Responses in Triple Combination

September 15, 2026